Dan Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Zheng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dongxin Xu
Fourth Department of Internal Medicine, Zibo City Traditional Chinese Medicine Hospital, China
1 shared publication - Gang Li
First Department of Oncology Surgery, Hangzhou Cancer Hospital, China
1 shared publication Hongyang Qi
Department of Gastroenterology, Xinxiang Central Hospital, Xinxiang, Henan, China
1 shared publication- Jinju Sun
Department of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, China
1 shared publication - Pengli Wang
Department of Gastroenterology, Xinxiang Central Hospital, Xinxiang, Henan, China
1 shared publication - Qi Gao
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China
1 shared publication
Latest Publications
- 17 May 2021
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 31 (1) , 27-38
miR-125b enhances metastasis and progression of cancer via the TXNIP and HIF1α pathway in pancreatic cancer
BACKGROUND: MicroRNAs (miRNAs) play potential role in the development of various types of cancer conditions including pancreatic cancer (PC) targeting several cellular processes. Present study was aimed to evaluate function of miR-125b and the mechanism involved in PC. METHODS: Cell migration, MTT and BrdU study was done to establish the migration capability, cell viability and cell proliferation respectively. Binding sites for miR-125b were recognized by luciferase assay, expression of protein by western blot and immunofluorescence assay. In vivo study was done by BALB/c nude xenograft mice for evaluating the function of miR-125b. RESULTS: The study showed that expression of miR-125b was elevated in PC cells and tissues, and was correlated to proliferation and migration of cells. Also, over-expression of miR-125b encouraged migration, metastasis and proliferation of BxPC-3 cells, the suppression reversed it. We also noticed that thioredoxin-interacting protein (TXNIP) was the potential target of miR-125b. The outcomes also suggested that miR-125b governed the expression of TXNIP inversely via directly attaching to the 3′-UTR activating hypoxia-inducible factor 1α (HIF1α). Looking into the relation between HIF1α and TXNIP, we discovered that TXNIP caused the degradation and export of HIF1α by making a complex with it. CONCLUSION: The miR-125b-TXNIP-HIF1α pathway may serve useful strategy for diagnosing and treating PC.
- 17 May 2021
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 31 (1) , 27-38
miR-125b enhances metastasis and progression of cancer via the TXNIP and HIF1α pathway in pancreatic cancer
BACKGROUND: MicroRNAs (miRNAs) play potential role in the development of various types of cancer conditions including pancreatic cancer (PC) targeting several cellular processes. Present study was aimed to evaluate function of miR-125b and the mechanism involved in PC. METHODS: Cell migration, MTT and BrdU study was done to establish the migration capability, cell viability and cell proliferation respectively. Binding sites for miR-125b were recognized by luciferase assay, expression of protein by western blot and immunofluorescence assay. In vivo study was done by BALB/c nude xenograft mice for evaluating the function of miR-125b. RESULTS: The study showed that expression of miR-125b was elevated in PC cells and tissues, and was correlated to proliferation and migration of cells. Also, over-expression of miR-125b encouraged migration, metastasis and proliferation of BxPC-3 cells, the suppression reversed it. We also noticed that thioredoxin-interacting protein (TXNIP) was the potential target of miR-125b. The outcomes also suggested that miR-125b governed the expression of TXNIP inversely via directly attaching to the 3′-UTR activating hypoxia-inducible factor 1α (HIF1α). Looking into the relation between HIF1α and TXNIP, we discovered that TXNIP caused the degradation and export of HIF1α by making a complex with it. CONCLUSION: The miR-125b-TXNIP-HIF1α pathway may serve useful strategy for diagnosing and treating PC.
- Open Access
- 3 December 2020
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 29 (11) , 1337-1345
Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway
Breast cancer has the highest incidence and mortality among all cancers in women. Paclitaxel (PTX) has a notable therapeutic effect on cancer in clinical practice. To explore the effect and mechanism of PTX on the proliferation, apoptosis and invasiveness of breast cancer cells. MCF-7 cells were treated with PTX (0 μM, 0.01 μM, 0.1 μM, 1 μM) for 48 h. Cell viability was detected using MTT assay and lactate dehydrogenase (LDH) assay; the cell proliferation rate was detected using 5-ethynyl-2'-deoxyuridine (EdU) assay to screen the most effective concentration of PTX. MCF-7 cells were then divided into 5 groups: control group, PTX group, oe-PI3K group, NC-PI3K group, and oe-PI3K+PTX group. Cell apoptosis and cell cycles were detected with flow cytometry; cell invasion was determined using a transwell assay; western blot and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to measure the mRNA and protein expression level of cleaved caspase-3, Bax, Bcl-2, matrix metalloproteinase 9 (MMP-9), vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473). Paclitaxel inhibited cell viability and proliferation in a dose-dependent manner. In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased. However, PI3K upregulation can reverse the effects of PTX. Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.
- 3 December 2020
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 29 (11) , 1337-1345
Open AccessPaclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway
Breast cancer has the highest incidence and mortality among all cancers in women. Paclitaxel (PTX) has a notable therapeutic effect on cancer in clinical practice. To explore the effect and mechanism of PTX on the proliferation, apoptosis and invasiveness of breast cancer cells. MCF-7 cells were treated with PTX (0 μM, 0.01 μM, 0.1 μM, 1 μM) for 48 h. Cell viability was detected using MTT assay and lactate dehydrogenase (LDH) assay; the cell proliferation rate was detected using 5-ethynyl-2'-deoxyuridine (EdU) assay to screen the most effective concentration of PTX. MCF-7 cells were then divided into 5 groups: control group, PTX group, oe-PI3K group, NC-PI3K group, and oe-PI3K+PTX group. Cell apoptosis and cell cycles were detected with flow cytometry; cell invasion was determined using a transwell assay; western blot and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to measure the mRNA and protein expression level of cleaved caspase-3, Bax, Bcl-2, matrix metalloproteinase 9 (MMP-9), vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473). Paclitaxel inhibited cell viability and proliferation in a dose-dependent manner. In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased. However, PI3K upregulation can reverse the effects of PTX. Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.